PDF(Pubmed)
Abstract：
UNASSIGNED: The effect of arginine on tumors appears to be bidirectional. The association of serum arginine with the risk of incident cancer remains uncovered at present. We aimed to investigate the prospective relationship of baseline serum arginine concentrations with the risk of incident cancer in hypertensive participants.
UNASSIGNED: A nested, case-control study with 1,389 incident cancer cases and 1,389 matched controls was conducted using data from the China H-Type Hypertension Registry Study (CHHRS). Conditional logistic regression analyses were performed to evaluate the association between serum arginine and the risk of the overall, digestive system, non-digestive system, and site-specific cancer.
UNASSIGNED: Compared with matched controls, cancer patients had higher levels of arginine (21.41 μg/mL vs. 20.88 μg/mL, p < 0.05). When serum arginine concentrations were assessed as quartiles, compared with participants in the lowest arginine quartile, participants in the highest arginine quartile had a 32% (OR = 1.32, 95% CI: 1.03 to 1.71), and 68% (OR = 1.68, 95% CI: 1.09 to 2.59) increased risk of overall and digestive system cancer, respectively, in the adjusted models. In the site-specific analysis, each standard deviation (SD) increment of serum arginine was independently and positively associated with the risk of colorectal cancer (OR = 1.35, 95% CI: 1.01 to 1.82) in the adjusted analysis.
UNASSIGNED: We found that hypertensive individuals with higher serum arginine levels exhibited a higher risk of overall, digestive system, and colorectal cancer.
UNASSIGNED: A nested, case-control study with 1,389 incident cancer cases and 1,389 matched controls was conducted using data from the China H-Type Hypertension Registry Study (CHHRS). Conditional logistic regression analyses were performed to evaluate the association between serum arginine and the risk of the overall, digestive system, non-digestive system, and site-specific cancer.
UNASSIGNED: Compared with matched controls, cancer patients had higher levels of arginine (21.41 μg/mL vs. 20.88 μg/mL, p < 0.05). When serum arginine concentrations were assessed as quartiles, compared with participants in the lowest arginine quartile, participants in the highest arginine quartile had a 32% (OR = 1.32, 95% CI: 1.03 to 1.71), and 68% (OR = 1.68, 95% CI: 1.09 to 2.59) increased risk of overall and digestive system cancer, respectively, in the adjusted models. In the site-specific analysis, each standard deviation (SD) increment of serum arginine was independently and positively associated with the risk of colorectal cancer (OR = 1.35, 95% CI: 1.01 to 1.82) in the adjusted analysis.
UNASSIGNED: We found that hypertensive individuals with higher serum arginine levels exhibited a higher risk of overall, digestive system, and colorectal cancer.
摘要：
未经证实：精氨酸对肿瘤的作用似乎是双向的。目前仍未发现血清精氨酸与偶发癌症风险的关联。我们旨在调查基线血清精氨酸浓度与高血压参与者发生癌症风险的前瞻性关系。
UNASSIGNED：嵌套，采用来自中国H型高血压登记研究(CHHRS)的数据,对1,389例癌症事件病例和1,389例配对对照进行病例对照研究.进行条件logistic回归分析以评估血清精氨酸与总体风险之间的关联。消化系统,非消化系统,和位点特异性癌症。
UNASSIGNED：与匹配的对照相比，癌症患者的精氨酸水平较高（21.41μg/mLvs.20.88μg/mL,p<0.05)。当血清精氨酸浓度被评估为四分位数时，与最低精氨酸四分位数的参与者相比，精氨酸四分位数最高的参与者有32％（OR=1.32，95％CI：1.03至1.71），68%（OR=1.68，95%CI：1.09至2.59）的整体和消化系统癌症风险增加，分别,在调整后的模型中。在特定地点的分析中，在校正分析中,血清精氨酸的每个标准差(SD)增量与结直肠癌的风险呈独立正相关(OR=1.35,95%CI:1.01~1.82).
未经评估：我们发现，血清精氨酸水平较高的高血压个体表现出更高的总体风险，消化系统,还有结直肠癌.
UNASSIGNED：嵌套，采用来自中国H型高血压登记研究(CHHRS)的数据,对1,389例癌症事件病例和1,389例配对对照进行病例对照研究.进行条件logistic回归分析以评估血清精氨酸与总体风险之间的关联。消化系统,非消化系统,和位点特异性癌症。
UNASSIGNED：与匹配的对照相比，癌症患者的精氨酸水平较高（21.41μg/mLvs.20.88μg/mL,p<0.05)。当血清精氨酸浓度被评估为四分位数时，与最低精氨酸四分位数的参与者相比，精氨酸四分位数最高的参与者有32％（OR=1.32，95％CI：1.03至1.71），68%（OR=1.68，95%CI：1.09至2.59）的整体和消化系统癌症风险增加，分别,在调整后的模型中。在特定地点的分析中，在校正分析中,血清精氨酸的每个标准差(SD)增量与结直肠癌的风险呈独立正相关(OR=1.35,95%CI:1.01~1.82).
未经评估：我们发现，血清精氨酸水平较高的高血压个体表现出更高的总体风险，消化系统,还有结直肠癌.
